Baylor Challenges HDAC Inhibitor Mechanism
Analysis based on 7 articles · First reported Jun 05, 2026 · Last updated Jun 24, 2026
The findings could lead to a re-evaluation of existing cancer treatments and drug development strategies, potentially impacting pharmaceutical companies involved in oncology. If new targets are identified, it could open up new avenues for drug discovery and investment in the biotechnology sector. The market sentiment for companies developing HDAC inhibitors might shift as their mechanism of action is better understood, potentially leading to more effective drug designs.
Researchers at Baylor College of Medicine, led by Dr. Zheng Sun and Dr. Chaitra Rai, are challenging the long-held belief that histone deacetylase (HDAC) inhibitors primarily function by blocking HDAC enzymes to treat cancer. Their study, published in Signal Transduction and Targeted Therapy, suggests that these drugs may also affect other pathways and interfere with other proteins to suppress cancer. The research indicates that HDACs are not consistently associated with cancer growth and that the anti-cancer effects of drugs like Romidepsin can be independent of HDAC inhibition. This discovery highlights the importance of identifying the genuine molecular targets of HDAC inhibitors to improve future cancer treatments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard